{"id":"W2995427723","doi":"10.1007/s12325-019-01169-0","title":"Response to Letter to the Editor Regarding: Indirect Treatment Comparison of Inotuzumab Ozogamicin versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia","year":2019,"lang":"en","type":"letter","venue":"Advances in Therapy","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"EVRAZ (Canada); TransCanada (Canada)","funders":"Pfizer","keywords":"Blinatumomab; Medicine; Refractory (planetary science); Lymphoblastic Leukemia; Internal medicine; Oncology; Salvage therapy; Pediatrics; Leukemia; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008964951,0.0009320582,0.002119381,0.001130007,0.0001398483,0.0000517327,0.001075891,0.001076185,0.00007065453],"category_scores_gemma":[0.001604745,0.0005711117,0.0004266998,0.001032984,0.0002228877,0.0002152149,0.0001709787,0.001467653,0.000158398],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.01254825,"about_ca_system_score_gemma":0.003483601,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007407931,"about_ca_topic_score_gemma":0.00009215335,"domain_scores_codex":[0.9942032,0.0006485308,0.001187463,0.001286753,0.001435927,0.001238186],"domain_scores_gemma":[0.9863237,0.01065313,0.000554012,0.001903984,0.0003814361,0.0001837112],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.1874244,0.0001932512,0.00008638884,0.0001655499,0.0006439509,0.0003055437,0.001511477,0.0004280195,0.002401317,0.000001377682,0.791771,0.01506769],"study_design_scores_gemma":[0.02977863,0.02084764,0.00009398568,0.0007290203,0.0002396816,0.00003087045,0.0001414616,0.0003489323,0.00907885,0.000009525362,0.9381359,0.0005655421],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.2640016,0.007917684,0.002392059,0.6648955,0.03557648,0.02279663,0.001254792,0.0003509997,0.0008142893],"genre_scores_gemma":[0.1109082,0.006451072,0.01048861,0.7548218,0.07006279,0.006369686,0.001256368,0.001360419,0.03828102],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.1576458,"threshold_uncertainty_score":0.999674,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03605871875456865,"score_gpt":0.3624977746121067,"score_spread":0.3264390558575381,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}